Indonesia’s largest a pharmaceutical company, PT Kalbe Farma Tbk (KLBF), is eyeing 17.5%-18.5% operating income margin this year.
In its public presentation submitted to Indonesia Stock Exchange this morning, it was mentioned that the company also targets 13%-15% sales growth this year assuming there is no divestment over its packaging division.
Kalbe Farma also targets net income per share as much as Rp130-Rp140 with 34%-44% growth. However, referring to the company’s performance as per June 2010, Kalbe posted 20% jump over its operating margin from 16.6% through the end of June 2009 to 17.8%.
The company also booked Rp572 billion net income during the first half this year compared to the same period last year amounting Rp399 billion. The company’s sales rose from Rp4.22 trillion to Rp4.71 trillion in the end of the first half 2010.
Disclosure: No position at the stock mentioned above.
Print This Article